Status:
COMPLETED
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran base...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Aged 18 years of age or older
- Elevated LDL-C despite statin therapy
- Other inclusion criteria per ongoing inclisiran clinical trials
Exclusion
Key Trial Info
Start Date :
March 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 9 2024
Estimated Enrollment :
1385 Patients enrolled
Trial Details
Trial ID
NCT07214857
Start Date
March 29 2024
End Date
October 9 2024
Last Update
October 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936